title: Combined oral and parenteral iron chelation in beta thalassaemia major.
abstract: Thalassaemics in Malaysia are poorly chelated because desferrioxamine is too expensive and cumbersome for long term compliance. The efficacy and tolerability of the oral chelator deferiprone, and the effects of using a combination therapy in our patients were studied. Ten patients completed the study and the mean serum ferritin reduced from 7066.11 ug/L (2577-12,896 ug/L) to 3242.24 ug/L (955-6120 ug/L). The liver iron concentration did not show a significant drop (19.6 vs 18.2 mg/g dry weight) although 3 patients showed reductions ranging from 30-40%. Concomitant use of desferrioxamine increased the urinary excretion from a mean of 13.66 mg/day to 27.38 mg/day. Main side effects seen were nausea and rashes.
authors.affiliation: Department of Paediatrics, Penang Hospital, Residency Road, 10450 Penang.
authors.forename: K
authors.initials: K
authors.lastname: Balveer
authors.forename: K
authors.initials: K
authors.lastname: Pyar
authors.forename: B
authors.initials: B
authors.lastname: Wonke
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002648:Child; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007279:Injections, Subcutaneous; D007501:Iron / Q000378:metabolism; D007502:Iron Chelating Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D008099:Liver / Q000378:metabolism; D008297:Male; D011728:Pyridones / Q000008:administration & dosage* / Q000627:therapeutic use; D017086:beta-Thalassemia / Q000097:blood / Q000188:drug therapy*
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine